Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clonality in acquired hematologic disorders.

D G Gilliland1, K L Blanchard, H F Bunn

  • 1Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Annual Review of Medicine
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms.

Blood cancer journal·2012
Same author

EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.

Leukemia·2011
Same author

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.

Leukemia·2011
Same author

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Leukemia·2010
Same author

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.

Leukemia·2009
Same author

PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors.

Leukemia·2009
Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026
Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026
Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026
Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026
Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026
Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026
See all related articles

Identifying clonal cell populations through various genetic analyses reveals insights into acquired hematologic disorders. A single mutation initiating clonal growth is a key, but not the sole, factor in malignancy development.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Clonal populations are crucial in understanding hematologic disorders.
  • Multiple genetic approaches exist for identifying these clonal cells.

Purpose of the Study:

  • To explore the role of clonality in the pathogenesis of acquired hematologic disorders.
  • To elucidate the multistep process in the development of hematologic malignancies.

Main Methods:

  • Analysis of karyotype
  • Gene rearrangements
  • Deletions or point mutations
  • X-linked polymorphisms
  • Viral integration into the genome

Main Results:

Related Experiment Videos

  • Clonality assessment provides insights into disease development.
  • Clonal expansion of mutated stem cells can lead to phenotypically normal blood cells.
  • Progression to acute leukemia often involves additional mutations.

    • Conclusions:

    • A mutation inducing clonal growth is a necessary but insufficient step in malignancy.
    • Multistep pathogenesis is supported in both myeloproliferative and lymphoproliferative disorders.